Ashina, Sait
Melo-Carrillo, Agustin
Toluwanimi, Ajayi
Bolo, Nicolas
Szabo, Edina
Borsook, David
Burstein, Rami
Funding for this research was provided by:
Eli Lilly and Company (32939, 32939, 32939, 32939, 32939, 32939, 32939)
Article History
Received: 10 February 2023
Accepted: 3 March 2023
First Online: 16 March 2023
Declarations
:
: All authors have completed the ICMJE uniform disclosure form at (available on request from the corresponding author).S.A. received honoraria for consulting from Allergan/AbbVie, Amgen, Biohaven, Eli Lilly, Impel NeuroPharma, Novartis, Satsuma, Supernus, Theranica, Percept.R.B. is the John Hedley-Whyte Professor of Anesthesia and Neuroscience at the Beth Israel Deaconess Medical Center and Harvard Medical School. He has received research support from the NIH: R01 NS094198-01A1, R37 NS079678, R01NS095655, R01 NS104296, R21 NS106345, Allergan, Teva, Dr. Reddy, Eli Lilly, Trigemina and the Migraine Research Foundation. He is a reviewer for NINDS, holds stock options in AllayLampand Percept; serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Biohaven, CGRP Diagnostic, Dr. Reddy’s Laboratory, ElectroCore, Eli Lilly, GlaxoSmithKline, Merck, Pernix, Theranica, Teva, and Trigemina. CME fees from Healthlogix, Medlogix, WebMD/Medscape, and Patents 9061025, 11732265.1, 10806890, US2021-0015908, WO21007165, US2021-0128724, WO21005497. DB has served as a consultant for Eli Lilly, Redpin Rx, and Luminous Mind.Other authors declare that they have no competing interests.